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ABSTRACT
Helicobacter pylori and Epstein-Barr virus (EBV) infections are common worldwide. Although H. 
pylori infection is a major factor in gastroduodenal diseases, its role in association with EBV infec-
tion is unknown. Objective: To study the association of H. pylori infection and EBV DNA load 
in patients with gastroduodenal diseases. Methods: Biopsy samples were collected from 200 adult 
patients [non-ulcer dyspepsia (NUD) 100, peptic ulcer disease (PUD) 50, gastric carcinoma (GC) 
50] undergoing upper gastrointestinal endoscopy. H. pylori infection was diagnosed by rapid urease 
test, culture, histopathology, PCR and Q-PCR. EBV DNA was detected by non-polymorphic Ep-
stein-Barr nuclear antigen-1 (EBNA-1) gene based Q-PCR. Results: In patients with GC and PUD, 
EBV DNA was detected more often than NUD (GC versus NUD = 90% versus 37%, p < 0.001; 
PUD versus NUD = 70% versus 37%, p < 0.001). The dual prevalence of H. pylori infection and EBV 
DNA was significantly higher in patients with GC and PUD than in those with NUD. Median copy 
number of EBV DNA was considerably higher in GC and PUD than NUD (p < 0.01). The copy num-
ber of EBV DNA was significantly higher in H. pylori infected patients (p = 0.015). The number of 
ureA gene copies was also found to be significantly higher in PUD and NUD with presence of EBV 
DNA. However, in GC no significant difference was seen between EBV positive and negative status. 
Conclusion: There was a trend for higher EBV DNA load in H. pylori positive individuals suggesting 
a probable role of H. pylori in modulating the conversion of EBV to its lytic phase.
Keywords: Epstein-Barr virus infections; stomach neoplasms; Helicobacter pylori.
INTRODUCTION
Epstein-Barr virus (EBV), a ubiquitous her-
pes virus, infects approximately 95% of the 
world’s population and is well documented to be 
causally associated with various malignant 
tumors, including Burkitt’s lymphoma, naso-
pharyngeal carcinoma, and B-cell lymphoma in 
immunodeficient individuals, and is also pro-
posed to play a causative role in gastric carcino-
ma, as is H. pylori.1 The EBV genome in patients 
with gastric carcinoma (GC) varies in different 
geographical regions, e.g. Europe (8.75%), Asia 
(7.99%) and America (11.2%).2 A higher preva-
lence of EBV associated GC was reported in the 
United States (16%) where GC risk is one of 
the lowest in the world. Countries like India 
(33.3%), Poland (28%), and Turkey (50.2%) 
also have a higher prevalence of EBV in GC 
patients.2-5 Based on these findings, it is argued 
that the areas with a low incidence of GC have 
a relatively high proportion of EBV in patients 
with GC.2 However, when meta-analysis was 
restricted to studies that used EBER-in situ 
hybridization (ISH) for EBV detection in gas-
tric carcinoma, no appreciable difference was 
seen in geographical prevalence rates and 
suggested that geographical differences are ac-
tually just differences in the methods of EBV 
detection.6 So, the methods used to detect the 
EBV DNA or EBV infection may potentially give 
rise to variations in the virus detection rate with-
in different tissues and disease groups. Nowa-
days, newer detection methods such as PCR and 
real-time PCR (Q-PCR) have also revolution-
ized the clinical microbiology laboratories to 
diagnose human pathogens even when they are 
present in small number of copies.7 Advantages 
over EBER-ISH are PCR’s relatively low cost, 
its applicability to specimens with poor-quality 
RNA, and its ability to detect (pure lytic) infec-
tion lacking EBER transcripts.8 Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
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Some authors also found increased rate of EBV 
infection in GC patients by using this technique.9-11 The as-
sociation of EBV with peptic ulcer disease (PUD), another 
important gastroduodenal disease, has not been clearly 
defined. However, some authors also reported EBV infec-
tion in preneoplastic gastric lesion, and gastritis regions.12-14
EBV can infect the cell in either latent or a lytic man-
ner. During the latent phase of the EBV viral life cycle, 
there is no production of infectious viruses and a highly 
restricted number of latent infection genes are expressed. 
Infectious viruses are produced during the lytic phase 
of EBV life cycle. Approximately 80 viral proteins are 
expressed during lytic viral replication, including 
transcriptional activators, DNA replication factors, and 
structural proteins such as viral capsid antigens.15 These 
events further increase the viral load of EBV. Recently it was 
reported in one study that H. pylori associated NH2Cl 
induces EBV lytic infection from latent infection in gas-
tric epithelium latently infected with EBV.16 Thus, it is 
of interest to determine whether H. pylori infection can 
affect the viral load of EBV in GC and PUD patients. So, 
in this study our aim was, firstly, to determine the EBV 
viral load in patients with GC and PUD; and, secondly, to 
correlate the EBV viral load to H. pylori infection. 
METHODS
Patient population
We enrolled 200 adult patients [non-ulcer dyspepsia 
(NUD) 100, PUD 50, GC 50] undergoing upper gastro-
intestinal endoscopies at Sanjay Gandhi Postgraduate 
Institute of Medical Sciences, Lucknow, between Novem-
ber 2005 to August 2009. The diagnosis of gastroduo-
denal diseases was based on clinical, endoscopic and 
histopathologic examinations. Patients with NUD were 
considered as controls in our study. The ethics commit-
tee of the institute granted approval for the study and all 
the patients gave their consent to participate. Subjects 
who had received antimicrobial therapy, H2-receptor 
blockers, proton-pump inhibitors and non-steroidal an-
ti-inflammatory drugs 30 days prior to endoscopy were 
excluded from the study.
Detection of EBV DNA
For EBV detection, gastric biopsies were collected from 
cancer as well as ulcer region of GC and PUD patients. 
Biopsies were also taken from the normal region of 
the stomach. Further DNA was extracted from these 
tissues with the QIAamp DNA mini kit (QIAGEN, Hilden, 
Germany). Q PCR was performed by targeting the non-
polymorphic Epstein-Barr nuclear antigen-1 (EBNA-1) 
gene using Corbett Research 6000 Q-PCR instrument 
and Rotor gene 6000 software. Primer sequences, probe 
and thermocycling conditions were taken from a previ-
ous work.8 Each 25 µL reaction contained 1x TaqMan 
Universal Master Mix, forward and reverse primer 
(15 ρmol each), and TaqMan probe (10 ρmol). DNA 
volume was 5 µL (1 µg) for gastric tissues. To check for 
amplicon contamination, every run contained at least 
two “no template” controls in which nuclease free H2O 
was used instead of the template. The reporter dye (FAM) 
signal was measured against the internal reference dye 
(ROX) signal to normalize the signals for non-PCR-relat-
ed fluorescence fluctuations that occur from well to well. 
Detection of H. pylori infection
During each endoscopic examination, antral biopsies 
from normal region of antrum were obtained and sub-
jected to the following tests: rapid urease test (RUT), 
culture, histopathology and H. pylori-specific ureA pol-
ymerase chain reaction (PCR) following the standard 
protocol as previously described.17 A Q-PCR assay was 
also performed targeting ureA gene of H. pylori by us-
ing Corbett Research 6000 instrument and Rotor gene 
6000 software. The sequence of primer, probe and thermo 
cycling conditions were taken from previous published 
literature.18 H. pylori infection was diagnosed if culture 
was positive or when at least two out of four other tests 
(RUT, histopathology, PCR and Q- PCR) were positive.
Construction of standards and calculation of 
copy number of EBV and ureA gene of H. pylori
For quantitation of the number of EBV copies, a 
standard curve was generated using 10-fold dilutions of 
bacterial plasmid DNA containing EBNA-1 sequence 
of EBV (kindly provided by University of Wisconsin-
Madison), varying from 1010 to 101 copies of EBV DNA, 
and for detection of the number of ureA copies of H. pylori, 
10-fold dilutions of DNA extracted from the H. pylori type 
strain (ATCC 26695), varying from 105 to 101 copies. 
Both these curves were considered acceptable if a differ-
ence of 3.3 ± 0.3 cycles was demonstrated between each 
of the 10-fold dilutions, and if the correlation coefficient 
was at least 0.99. A commercially available Q-PCR assay 
targeting human GAPDH gene was used (Genome di-
agnostic Pvt. Ltd. India) to control the efficacy of DNA 
extraction and to normalize the number of cells amplified 
per reaction. EBV viral load and copy number of ureA 
gene in tissue were calculated based on the following 
formula: (number of EBV or ureA copies) / [(number of 
human GAPDH copies)/2]. The resulting ratio was then 
multiplied by 100,000 to provide the number of copies 
of EBV and ureA gene per 100,000 cells. Quantification 
results for experimental samples were extrapolated from 
the standard curve. Experimental samples were run in 
duplicate and a median viral load was calculated.
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Histopathology
Sections of 5 µm were cut from formalin fixed biopsy, 
embedded in paraffin. The sections were stained with he-
matoxylin and eosin for light microscopy for the presence 
of H. pylori infection. Patients with GC were confirmed 
by histopathology and classified into intestinal, diffuse 
and mixed according to the Lauren classification.19
Statistical analysis
Data were analyzed using SPSS software (version 12.0, 
SPSS, Chicago, IL., USA). H. pylori and EBV status in re-
lation to gastroduodenal diseases and histological types 
of GC was assessed by Chi square test. The number of 
copies of EBV DNA and ureA gene of H. pylori were com-
pared with the Mann-Whitney rank sum test. All the 
p-values were two sided and considered significant when 
less than 0.05. 
RESULTS
Patient characteristics
Demographic parameters of the 200 patients enrolled in the 
study are presented in Table 1.
Detection of H. pylori infection
H. pylori infection was significantly higher in patients 
with PUD than in those with GC (p = 0.044) and NUD 
(p < 0.001); however, no difference was observed between 
GC and NUD (p = 0.083) (Table 2). The median ureA 
copy of H. pylori in PUD was significantly higher than 
GC [PUD versus GC, 3887 (interquartile range 428 to 
26327) versus 2100 (interquartile range 225 to 3428.95); 
p = 0.028)]. The median copy number of ureA was also 
higher in NUD, when compared to GC, but we could 
not reach at significant level [NUD versus GC 3724 
Table 1. Demographic characteristics of patients included in the study
Parameters Non-ulcer Peptic ulcer  Gastric) Total (200) 
 dyspepsia (n = 100) disease (n = 50) carcinoma (n = 50)
Mean age ± SD 
43.86 ± 14.576 48.08 ± 16.491 52.43 ± 12.378 55.72 ± 13.837
 
(years)
Male 62 (62%) 34 (68%) 36 (72%) 132 (66%)
Female 38 (38%) 16 (32%) 14 (28%) 68 (34%)
Table 2. Presence of Helicobacter pylori, Epstein-Barr virus (EBV) and dual agents (H. pylori and EBV DNA) in 
patients with gastroduodenal diseases
Disease                        H. pylori infection*                     EBV DNA**                     
Dual agent *** 
                        (H. pylori and EBV DNA)
 + - + - + -
NUD 46/100 54/100 37/100 63/100 23/100 77/100 
(n = 100) (46) (54) (37) (63) (23) (77)
PUD 41/50 9/50 35/50 15/50 31/50 9/50 
(n = 50) (82) (18) (70) (30) (62) (38)
GC 31/50 19/50 45/50 5/50 27/50 23/50 
(n = 50) (62) (38) (90) (10) (54) (46)
Total 118/200 82/200 113/200 87/200 81/200 119/200 
(n = 200) (59) (41) (56.5) (43.5) (40.5) (59.5)
H. pylori infection*, PUD versus NUD: (82% versus 46%, p < 0.001); GC versus NUD: (62% versus 46%, p = 0.083); PUD versus GC: 
(82% versus 62 %, p = 0.044);
EBV DNA**, PUD versus NUD: (70% versus 37%, p < 0.001); GC versus NUD: (90% versus 37%, p < 0.001); GC versus PUD: (90% 
versus 70%, p = 0.023);
Dual agents (H. pylori and EBV DNA)***, PUD versus NUD: (62% versus 23%, p < 0.001); GC versus NUD: (54% versus 23%,  
p < 0.001).
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(interquartile range 672.31 to 20500) versus 2100 (inter-
quartile range 225 to 3428.95) (p = 0.074)] (Figure 1A).
Detection of EBV DNA
The detection of EBV DNA was based on amplification 
of the non-polymorphic Epstein-Barr nuclear antigen-1 
(EBNA-1) gene by Q-PCR. The frequency of EBV DNA 
in our study population was 56.5%. A significantly high-
er number of patients with GC and PUD had EBV DNA 
in comparison with patients with NUD (p < 0.001). The 
EBV infection rate was also found to be significantly 
higher in GC patients when compared to PUD (p = 0.023) 
(Table 2). The median copy number of EBV DNA in our 
population was 449.80. The median copy number in GC 
and PUD patients was found to be significantly higher 
when compared to NUD [GC versus NUD, 1329.18 (in-
terquartile range 158 to 5601) versus 86.79 (interquartile 
range 36.34 to 386.74); p < 0.001 and PUD versus NUD 
754.00 (interquartile range 290 to 2324) versus 86.79; 
p < 0.001]. However no difference was found between GC 
and PUD (p = 0.636) (Figure 2A). Data were also ana-
lyzed between normal and cancer/ulcer tissue. Out of 50 
GC patients, none of them presented a detectable copy 
number of EBV DNA in normal mucosa. However out 
of 50 PUD patients, 7 (14%) had detectable EBV DNA in 
their normal mucosa. The median copy number of EBV 
DNA was significantly higher in ulcer tissue when com-
pared to normal mucosa [ulcer versus normal tissue 1759 
(interquartile range 367.50 to 5854) versus 95 (interquar-
tile range 27.75 to 462.50); p = 0.01] (Figure 2C).
Figure 1: Calculation of ureA gene copy number of H. pylori (per 1000,000 cells). (A) shows the median copy number of ureA 
in GC, PUD and NUD. The copy number was compared between GC and PUD (p = 0.028), PUD and NUD (p = 0.507) and GC and 
NUD (p = 0.074). (B) shows the comparison of ureA copy number between EBV infected and non infected patients (p = 0.006). (C) 
shows the comparison of ureA copy number in ulcer and normal tissue of same patients (p = 0.01) and (D) shows the disease wise 
difference in copy number of ureA in presence and absence of EBV. In each panel, the lines inside the boxes denote the medians, 
the boxes denote the interquartile ranges, and the I bars indicate the 10th and 90th percentiles.
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Figure 2: Calculation of median copy number of EBV DNA (per 1000,000 cells). (A) shows the median copy number of EBV DNA 
in GC, PUD and NUD patients. The copy number was compared between GC and PUD (p = 0.001), PUD and NUD (p = 0.001) and 
GC and NUD (p = 0.636). (B) shows difference in median copy number of EBV DNA in H. pylori positive and negative patients 
(p = 0.015*). (C) shows the difference in median copy number of EBV DNA in ulcer and normal tissue (p = 0.01) and (D) shows 
the disease wise difference in EBV DNA in presence and absence of H. pylori. In each panel, the lines inside the boxes denote the 
medians, the boxes denote the interquartile ranges, and the I bars indicate the 10th and 90th percentiles.
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Measurement of EBV viral load and its relation to 
H. pylori infection
The dual infection by H. pylori and EBV was significantly 
higher in patients with GC and PUD than in those with NUD 
(p < 0.001). The overall dual prevalence of H. pylori infec-
tion and EBV DNA in our study population was 40.5%. 
H. pylori infection alone was not significantly related 
to GC but the presence of H. pylori infection and EBV 
DNA was associated with both GC and PUD (Table 2). 
In overall study population, the median copy number of 
EBV DNA in H. pylori infected patients was significant-
ly higher than uninfected patients [H. pylori positive v/s 
H. pylori negative patients, 519.35 (interquartile range 151 
to 2544) versus 177.80 (interquartile range 49.99 to 697.60); 
p = 0.015] (Figure 2B). However, no difference was observed 
when the data were analyzed in individual disease group be-
tween H. pylori infected versus non-infected patients (Figure 2C). 
In overall study population the median copy number 
of ureA gene of H. pylori was significantly higher in EBV 
positive patients when compared to the EBV negative pa-
tients [EBV positive versus EBV negative, 2500 versus 1329 
(p = 0.006)] (Figure 1C). Same observation was also seen 
(except GC) when data analyzed in individual disease group 
between EBV infected and non-infected patients (Figure 1D).
Histological findings in patients with GC and  
measurement of EBV viral load
Patients with GC were confirmed by histopathology and 
classified into intestinal, diffuse and mixed type according 
to the Lauren classification. The distribution of different 
types of GC was as follows: intestinal type 24 (48%), dif-
fuse type 26 (52%). None of our patients had mixed type 
of adenocarcinoma. Detection of EBV genome was almost 
in equal proportion in both the diffuse (92.3%) and the 
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intestinal (87.5%) GC types. The prevalence of H. pylori 
infection and EBV DNA tended to be somewhat similar in 
intestinal (58.3%) and in diffuse type (53.8%) of GC with 
no significant difference. The median copy number of EBV 
DNA and ureA was also similar in both diffuse as well as 
intestinal type of carcinoma with no significant difference. 
EBV DNA: [intestinal versus diffuse; 690 (interquartile range 
169.85 to 2541.81) versus 2373.4190 (interquartile 
range 150.35 to 9675) (p = 0.382)]. ureA: [intestinal versus 
diffuse; 1544 (interquartile range 210 to 4242.40) versus 
2100 (interquartile range 450 to 2500) (p = 0.790)] (Figure 1B).
DISCUSSION
The aim of present study was to compare the EBV DNA load 
with H. pylori infection in patients with GC and PUD. A 
significantly higher number of patients with GC (90%) and 
PUD (70%) had EBV DNA when compared to NUD (37%). 
The EBV DNA load was also found to be significantly higher 
in these disease groups. However, we did not found any EBV 
DNA in normal tissue of GC patients. Previous studies also 
did not found any EBV DNA in preneoplastic or normal 
mucosa of GC patients and suggested that EBV infection 
of gastric epithelial cells is not an early event in gastric car-
cinogenesis.11,20 However, in PUD, a significantly lower copy 
number of EBV DNA was detected in normal tissue when 
compared to ulcer tissue. To the best of our knowledge this 
is the first study which compared the EBV DNA load both in 
normal as well as ulcer tissue in PUD patients. The paucity 
of data in the world literature did not allow comparison of 
our figures with other studies addressing the prevalence and 
load of EBV DNA in patients with NUD and PUD. How-
ever, few studies also reported EBV DNA in normal gastric 
mucosa other than GC and concluded that the gastric epi-
thelium is frequently infected with EBV and prolonged EBV 
persistence may contribute to the development of gastric 
carcinogenesis.12-14
EBER-ISH is the gold standard for EBV detection in 
biopsy specimen.7 However, the sensitivity of EBER stain-
ing has been called into question by investigators who have 
shown, by molecular or immunohistochemical assays, that 
EBV is present in some EBER-negative tumors.21-23 The 
sensitivity of this assay also depends on the viral load 
and sensitivity of assay decreases when virus is present in low 
copy number.11 Recently in America, EBV DNA was detect-
ed by Q-PCR in 64% of United States and in 100% Central 
America GC which are concordant with our current find-
ing. This study also concluded that the Q-PCR amplification 
technology is better than EBER-ISH for identifying cases of 
GC that are EBV related.24 We also analyzed the load of EBV 
DNA in two histological types of GC. No difference in the 
presence of EBV DNA was observed in our GC patients with 
either diffuse (92.3%) or intestinal type (87.5%). The data are 
concordant with the earlier studies on GC.25,26 Although the 
median concentration of EBV was higher in diffuse type than 
intestinal type, but we could not reach at significant level.
Currently, only a few studies have investigated the inter-
action of EBV and H. pylori infection in GC, but they did 
not found any association of these two pathogens.9,27,28 How-
ever, few studies reported that chronic atrophic gastritis and 
subsequent intestinal metaplasia caused by H. pylori infection 
enhances the susceptibility of EBV to gastric mucosal epi-
thelia, and then EBV facilitated the carcinogenesis of gastric 
carcinoma.13-14 Recently, it was reported in one study that 
H. pylori associated NH2Cl induces EBV lytic phase conver-
sion in gastric epithelium latently infected with EBV.16 In our 
study, we simultaneously detected the status of H. pylori in-
fection and the load of EBV DNA in patients with GC and 
PUD. Further we also compared the copy number of ureA 
gene of H. pylori in EBV infected and non infected patients. 
Ethically, healthy individuals without upper gastrointestinal 
symptoms should not be subjected to endoscopies, hence 
patients with NUD undergoing endoscopies were consid-
ered as controls. H. pylori infection rate in our study popula-
tion was higher (59%) than earlier report (53.4%).29 This is 
most likely due to the use of Q-PCR in the present study. 
The prevalence of H. pylori in GC reported in our study was 
low, as was reported by Sipponen et al.,30 but similar to oth-
er studies.31-33 Other studies from India also failed to show 
an association between H. pylori infection and GC.34-36 The 
chances of finding H. pylori in the biopsy specimens become 
less likely when the changes in chronic atrophic gastritis and 
intestinal metaplasia set in the stomach. These changes lead 
to absence of or a decrease in the H. pylori load in the stom-
ach, probably due to the lack of nutrients for this organism.37 
In addition, bacteria may be hidden within the mucosal cells 
and without producing urease in the lumen.38 So, these may 
be the probable reasons for the low prevalence as well as 
lower copy number ureA gene of H. pylori infection when a 
tissue based diagnosis is made in GC patients.
The dual prevalence of H. pylori infection and EBV DNA 
was significantly higher in patients with GC (54%) and PUD 
(62%) than in those with NUD (23%). Interestingly, we found 
that the presence of H. pylori infection and EBV DNA was asso-
ciated with both GC and PUD. So, it is hypothesized that inter-
action between H. pylori and EBV may have some synergistic 
mechanism in the pathogenesis of the disease.
In our study the copy number of EBV DNA was significant-
ly higher in H. pylori infected patients than uninfected patients. 
But we could not found significant association of H. pylori with 
copy number of EBV DNA in individual patient group. Howev-
er, in contrast to these findings copy number of ureA gene was 
significantly associated with EBV infection in PUD and NUD. 
We found increment of EBV DNA load in H. pylori 
infected patients, which somehow supported our current 
hypothesis. However, it is unclear that this increment was 
due to the reactivation of EBV. An alternative explanation 
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for higher EBV viral loads in diseased tissue could be a 
simple increase in the number of EBV positive cells rather 
than amplification of virus itself through lytic replication. 
Another thought might be that what if NUD somehow 
prevents EBV infection? Because this is a preliminary 
study, it is necessary to further explore EBV reactivation 
and some host factors to reach any conclusion. Moreover, 
virulence properties of H. pylori other than the urease 
are also required to know the exact interactions between 
H. pylori and EBV.
In conclusion, the trend of EBV DNA load was higher 
in H. pylori positive individuals suggesting the probable role 
of H. pylori in modulating the conversion of EBV to its lytic 
phase. Hence, there is a need to explore latent and lytic phase 
of EBV in relation to H. pylori infection and other factors, if 
any. However, further studies on larger patient populations 
are also required to know the exact interactions between the 
two most common gastric pathogens.
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